Search Results for: CLINICAL TRIALS Accelerating the Clinical
Articles
Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases June 11, 2020
Ovid Therapeutics Inc. recently announced a strategic research collaboration with Columbia University Irving Medical Center researchers to advance genetic based therapies for……
Appili Therapeutics Acquires Clinical-Stage Program From FUJIFILM Toyama Chemical November 21, 2019
Appili Therapeutics Inc. recently announced it has signed an agreement with FUJIFILM Toyama Chemical Co., Ltd. to acquire and develop the novel……
Oncologie Closes $80-Million Financing for Clinical-Stage Pipeline June 13, 2019
Oncologie recently announced it has closed an $80M Series B financing. Existing investors, led by Nan Fung Life Sciences and...TRANSLATIONAL PHARMACEUTICS - Accelerating Early-Stage Drug Development With Integrated CDMO & CRO Services January 9, 2019
Peter Scholes, PhD, describes the current challenges and questions faced by drug developers in accelerating molecules to POC and developing optimized and scalable drug products for patient trials.
EXECUTIVE INTERVIEW - MilliporeSigma: Accelerating the Development & Manufacture of Gene Therapies, Immunotherapies & Viral Vaccines April 2, 2018
Dave Backer, Head of Virus & Gene Therapy Strategic Initiatives at MilliporeSigma, talks about his company’s expanding GMP capacity to speed development and manufacture of gene therapies, immunotherapies, and viral vaccines.
CLINICAL TRIALS - Inconsistencies Prevalent in Study Start-Up April 2, 2018
Craig Morgan believes as stakeholders are increasingly aware that better study start-up (encompassing the activities associated with site identification, feasibility assessment, selection, and activation) processes are linked to shorter clinical timelines, the emphasis has been shifting in that direction.
Elligo Health Research Raises $16 Million to Improve Access to Clinical Trials March 23, 2018
Elligo Health Research, which improves clinical trial access by engaging the 97% of physicians currently not offering clinical research to...Roivant Sciences Launches Datavant to Improve Clinical Trials With Artificial Intelligence September 20, 2017
Roivant Sciences recently announced the launch of Datavant, a new company focused on employing artificial intelligence to improve the clinical...GNT Biotech & Medicals Corporation to Begin Phase III Clinical Trial April 24, 2017
GNT Biotech & Medicals Co., Ltd. recently announced that the anticancer drug Chidamide (HBI-8000), an epigenetic regulator developed by Chipscreen...Accelerating Development of Enabled Formulations for Poorly Soluble Drugs March 8, 2017
Efficacy issues due to inadequate gastrointestinal (GI) absorption caused by insufficient aqueous solubility are encountered in up to 70% of...Accelerating Development of Enabled Formulations for Poorly Soluble Drugs March 8, 2017
Efficacy issues due to inadequate gastrointestinal (GI) absorption caused by insufficient aqueous solubility are encountered in up to 70% of...Bend Research & Xcelience Form Partnership to Speed Drug Product Intermediates to Early Phase Clinical Trials August 25, 2011
Bend Research Inc. and Xcelience LLC recently announced they have formed a collaboration to provide oral solid-solubilization formulation solutions and...BC Platforms & NTT Group Announce Official Opening Ceremony for Exclusive Collaboration & Launch of Japanese Precision Medicine Platform April 15, 2024
BC Platforms (BCP) recently announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven….
MoonLake Immunotherapeutics Signs 3-Year Technology Partnership With Komodo Health April 10, 2024
MoonLake Immunotherapeutics and Komodo Health recently announced a new technology partnership to help improve treatment for people living with inflammatory...Teva & Abingworth Enter Strategic Development Funding Agreement April 1, 2024
Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler (TEV-‘248) program….
SPECIAL FEATURE - Excipients: Advanced Biologics Require Innovative Excipient Science March 29, 2024
Contributor Cindy H. Dubin speaks with several leading companies to discuss novel and functional excipients being developed, the role they will play in reformulations and new formulations, and their versatility in drug delivery.
THERAPEUTIC FOCUS - TTHX1114: Improving Outcomes for High-Risk Patients After Cataract Surgery February 28, 2024
David Eveleth, PhD, says in many cases, high-risk patients have few options for complication-free treatment of cataracts or other degenerative eye disorders. By filling this unmet need, TTHX1114 has the potential to significantly improve vision health, enhance the well-being of high-risk individuals, and alleviate economic burden on healthcare systems and economies.
PathAI Announces Exclusive Collaboration With Roche Tissue Diagnostics to Advance AI-enabled Interpretation for Companion Diagnostics February 14, 2024
PathAI, Inc. recently announced an expanded and exclusive relationship with Roche Tissue Diagnostics (RTD) that will bring AI-enabled interpretation to companion...DRUG DEVELOPMENT - Using a Novel Deep Cyclic Inhibition Mechanism to Treat Broad Range of RAS-Mutant Cancers January 26, 2024
Ben Zeskind, PhD, addresses the question: rather than targeting individual RAS mutations and treating chronically, is it possible to achieve broad therapeutic activity in a way that focuses on malignant cells while minimizing damage to healthy cells?
Abzena Launches AbZelect Platforms for Improving Cell Line Development Efficiency on the Pathway to IND January 16, 2024
Abzena has launched AbZelect and AbZelectPRO cell line development (CLD) platforms for accelerating the generation of production cell lines for manufacture of antibodies and recombinant proteins. The platforms will….
WHITEPAPER: Lonza Engine® & Xcelodose®: Accelerating Preclinical & Clinical Trial Pathways With Target Dosing Technologies
Learn how Lonza helps developers quickly assess new drug candidates while minimizing API consumption through efficient excipient screenings, encapsulation and...
